(Total Views: 558)
Posted On: 09/25/2025 12:18:19 AM
Post# of 157259
Am I correct in finding thru AI that trodelvy and Keytruda both had a 1 yr survival rate in heavily pretreated mTNBC of 25%? Am I reading this right?
(so the addition of LL increases 1 yr survival rate approx 50% from that level?)
from AI question "how many heavily pretreated mTNBC patients are currently alive after 1 year with current SOC?"
Several targeted therapies, especially antibody-drug conjugates (ADCs), are now considered SOC for heavily pretreated mTNBC, having improved upon the survival rates previously seen with standard chemotherapy alone.
Sacituzumab govitecan (Trodelvy): This ADC is a common SOC for patients who have already received multiple lines of therapy. Recent real-world data from June 2024 shows the following one-year overall survival (OS) rates for patients receiving sacituzumab govitecan:Heavily pretreated (\(3^{rd}\) line or more): 1-year OS rate of approximately 25%.Pretreated (\(2^{nd}\) line): 1-year OS rate of approximately 51%.Median OS: The ASCENT clinical trial, which led to the approval of sacituzumab govitecan, found a median OS of 11.8 months for heavily pretreated patients, a significant improvement over standard chemotherapy.
Pembrolizumab (Keytruda): This immunotherapy drug, when combined with chemotherapy, is a first-line treatment option for patients whose tumors express the PD-L1 protein. For heavily pretreated patients, a study found a one-year survival rate of approximately 25% with this treatment.
(so the addition of LL increases 1 yr survival rate approx 50% from that level?)
from AI question "how many heavily pretreated mTNBC patients are currently alive after 1 year with current SOC?"
Several targeted therapies, especially antibody-drug conjugates (ADCs), are now considered SOC for heavily pretreated mTNBC, having improved upon the survival rates previously seen with standard chemotherapy alone.
Sacituzumab govitecan (Trodelvy): This ADC is a common SOC for patients who have already received multiple lines of therapy. Recent real-world data from June 2024 shows the following one-year overall survival (OS) rates for patients receiving sacituzumab govitecan:Heavily pretreated (\(3^{rd}\) line or more): 1-year OS rate of approximately 25%.Pretreated (\(2^{nd}\) line): 1-year OS rate of approximately 51%.Median OS: The ASCENT clinical trial, which led to the approval of sacituzumab govitecan, found a median OS of 11.8 months for heavily pretreated patients, a significant improvement over standard chemotherapy.
Pembrolizumab (Keytruda): This immunotherapy drug, when combined with chemotherapy, is a first-line treatment option for patients whose tumors express the PD-L1 protein. For heavily pretreated patients, a study found a one-year survival rate of approximately 25% with this treatment.
(5)
(0)
